Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study

Background and objectives: It was postulated that in patients with membranous nephropathy (MN), four weekly doses of Rituximab (RTX) would result in more effective B cell depletion, a higher remission rate, and maintaining the same safety profile compared with patients treated with RTX dosed at 1 g...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Fervenza, Fernando C., Abraham, Roshini S., Erickson, Stephen B., Irazabal, Maria Valentina, Eirin, Alfonso, Specks, Ulrich, Nachman, Patrick H., Bergstralh, Eric J., Leung, Nelson, Cosio, Fernando G., Hogan, Marie C., Dillon, John J., Hickson, LaTonya J., Li, Xujian, Cattran, Daniel C.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Nephrology 2010
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2994079/
https://ncbi.nlm.nih.gov/pubmed/20705965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.05080610
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars